Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
Aged
Antigens, Neoplasm
/ analysis
Antineoplastic Agents
/ therapeutic use
Bevacizumab
/ administration & dosage
Biomarkers, Pharmacological
/ analysis
Biomarkers, Tumor
/ analysis
Carcinoembryonic Antigen
/ analysis
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Disease Progression
Female
Humans
Keratin-19
/ analysis
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Predictive Value of Tests
Prognosis
Retrospective Studies
Serpins
/ analysis
Treatment Outcome
Bevacizumab
CEA
CYFRA
NSCLC
SCC
predictive
prognostic
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
01
2021
revised:
17
02
2021
accepted:
18
02
2021
entrez:
4
4
2021
pubmed:
5
4
2021
medline:
28
4
2021
Statut:
ppublish
Résumé
To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy. We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival. In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.
Identifiants
pubmed: 33813413
pii: 41/4/2053
doi: 10.21873/anticanres.14974
doi:
Substances chimiques
Antigens, Neoplasm
0
Antineoplastic Agents
0
Biomarkers, Pharmacological
0
Biomarkers, Tumor
0
Carcinoembryonic Antigen
0
KRT19 protein, human
0
Keratin-19
0
Serpins
0
antigen CYFRA21.1
0
squamous cell carcinoma-related antigen
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2053-2058Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.